Particle.news
Download on the App Store
9 ARTICLES
·
last wk.

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.

Image
Image
Sanofi will pay $129 per share in cash, the companies said in a statement Monday.
Image

Overview

  • Sanofi will pay $129 per share in cash, representing a 27% premium to Blueprint’s last closing price, for an equity value of $9.1 billion.
  • Blueprint shareholders will receive one non-tradeable contingent value right per share tied to BLU-808 development and regulatory milestones, potentially unlocking up to $400 million.
  • Ayvakit (avapritinib), Blueprint’s only approved therapy for advanced and indolent systemic mastocytosis, generated $478.95 million in net revenues in 2024.
  • Pipeline assets such as elenestinib, a selective KIT D816V inhibitor, and BLU-808, a wild-type KIT inhibitor, will broaden Sanofi’s rare disease and immunology offerings.
  • Sanofi plans to finance the deal with cash on hand and new debt and expects no significant impact on its 2025 financial guidance.